Six-month regimens that include rifampin for the treatment of tuberculosis in patients without human immunodeficiency virus (HIV) infection are recommended because of low percentage of relapses. Whether a similar duration of therapy should be used to treat tuberculosis in HIV-infected patients is unclear. Six studies of patients with HIV-infection and 3 of patients without HIV infection were reviewed and compared. The studies differed in terms of design, eligibility criteria, site of disease, frequency of dosing, dose administration methods, and outcome definitions. Among HIV-infected patients, the following percentages were found: cure, 59.4%-97.1%; treatment success, 34.0%-100%; effective treatment, 29.4%-88.2%; and relapse, 0%-10%. In those without HIV infection, percentages were as follows: cure, 62.3%-88.0%; treatment success, 91.2%-98.8%; effective treatment, 70.6%-83.8%; and relapse, 0%-3.4%. Although the rate of relapse appeared to be higher in some studies of HIV-infected patients with tuberculosis, this review demonstrates the limitation in the use of relapse as the exclusive outcome of interest when comparing studies.
Six-month regimens that include rifampin for the treatment of tuberculosis in patients without human immunodeficiency virus (HIV) infection are recommended because of low percentage of relapses. Whether a similar duration of therapy should be used to treat tuberculosis in HIV-infected patients is unclear. Six studies of patients with HIV-infection and 3 of patients without HIV infection were reviewed and compared.
The studies differed in terms of design, eligibility criteria, site of disease, frequency of dosing, dose administration methods, and outcome definitions. Among HIV-infected patients, the following percentages were found: cure, 59.4%-97.1%; treatment success, 34.0%-100%; effective treatment, 29.4%-88.2%; and relapse, 0%-10%. In those without HIV infection, percentages were as follows: cure, 62.3%-88.0%; treatment success, 91.2%-98.8%; effective treatment, 70.6%-83.8%; and relapse, 0%-3.4%. Although the rate of relapse appeared to be higher in some studies of HIV-infected patients with tuberculosis, this review demonstrates the limitation in the use of relapse as the exclusive outcome of interest when comparing studies.
Tuberculosis requires many months of therapy to prevent the relapse of disease [1, 2] . Over the past several decades, efforts have focused on a reduction of the number of doses and a decrease in the duration of therapy [3] . Shortening the duration of therapy and using intermittent dosing can decrease the cost of treatment and facilitate the use of directly observed therapy (DOT) to promote adherence to treatment. These practical advances in treatment have contributed to the promotion by the World Health Organization of the DOT/ short-course strategy in an attempt to stem the global tuberculosis epidemic [4] . This strategy involves the use of standardized short-course regimens, in conjunction with other tuberculosis control measures, including adequate drug supply, proper monitoring and outcome evaluation, and government commitment.
The HIV epidemic has had a major impact on the worldwide incidence of tuberculosis [5] [6] [7] , because HIV infection is the most potent risk factor for the development of tuberculosis [8] . In countries such as those in sub-Saharan Africa, where tuberculosis is endemic and HIV incidence has markedly increased, tuberculosis has become the major opportunistic infection among HIV-infected persons, contributing to high mortality rates [6] . A dramatic increase in the rate of tuberculosis is also occurring in some Asian countries that are experiencing a rapid spread of HIV infection [9] . Therefore, the development of successful strategies for the prevention, diagnosis, and treatment of tuberculosis in patients infected with HIV (hereafter, "HIV-related tu-berculosis") has assumed global importance. Several issues have received attention, including the effect of tuberculosis on progression of HIV infection and on the survival rates of HIVinfected patients, the difficulties in diagnosis of tuberculosis in patients with HIV infection, and the ability of these patients to tolerate tuberculosis treatment [10] .
One of the most important issues that remains controversial is whether 6 months of treatment with regimens that include rifampin can effectively and safely treat HIV-related tuberculosis. The ability to use this short-course regimen for HIVinfected patients could allow programs to provide DOT to a larger number of patients, and it also would allow programmatic efficiency in the treatment of patients both with and without HIV infection with the same duration of therapy. The guidelines that the American Thoracic Society/Centers for Disease Control and Prevention published in 1994 recommended 6 months of therapy for drug-susceptible tuberculosis regardless of the patient's HIV status [1] . This recommendation was based on little experience with use of 6-month regimens in the treatment of HIV-infected patients. Although several studies published subsequently have assessed 6 months of therapy among HIV-infected patients, considerable uncertainty regarding the efficacy of this regimen remains, because these studies have varied in design, in the type of populations enrolled, and in the assessment of treatment outcomes [11] . To synthesize the available data, we reviewed 6 prospective studies of 6-month regimens that included rifampin for the treatment of HIVrelated tuberculosis and 3 selected studies of 6-month regimens of rifampin among HIV-uninfected patients to compare and contrast study design and findings. We examined the study methodologies, eligibility criteria, case and end point definitions, and study results.
METHODS

Studies Reviewed
Studies of HIV-related tuberculosis. We reviewed all 6 prospective studies that evaluated 6 months of therapy that included rifampin for the treatment of HIV-related tuberculosis, and which included data on both treatment and followup phases [12] [13] [14] [15] [16] [17] . These studies were conducted in Zaire, the Ivory Coast, Uganda, Haiti, and the United States (2), respectively. These studies were included irrespective of the differences in study design. For each trial, we assessed the study design, including eligibility criteria, follow-up schedule, methods of administration of medications, schedule of treatment, and definition of outcomes. The review of the results included the number of patients eligible, patient characteristics, proportion who completed the treatment phase, duration of follow-up, the number of losses to follow-up and death, and the proportion of patients who experienced failure of treatment or relapse. The data were abstracted or calculated on the basis of information available in the publications.
Studies of the treatment of tuberculosis in patients without HIV infection. To compare and contrast the results of 6 months of therapy that included rifampin in HIV-infected patients, we also reviewed 3 studies of 6 months of therapy that included rifampin in patients not infected with HIV [18] [19] [20] . These studies were selected because they assessed a regimen similar to those used in the aforementioned studies of patients with HIV infection. The first 2 studies were conducted in the United States and were key tuberculosis treatment studies. The first study was a multicenter randomized trial conducted throughout the United States by the Centers for Disease Control and Prevention (USPHS 21) [18] , the second study was conducted in Denver [19] , and the third study was conducted in Poland [20] . The latter 2 studies were prospective observational studies; all 3 were reviewed in the same manner as described for the studies of HIV-related tuberculosis.
Definitions of Outcomes
Several outcomes were assessed in our review of these studies. Some studies presented the outcome data directly, whereas others presented data points that enabled calculation of these outcomes. In situations in which the data did not clearly show the needed values, estimates were made, and these are indicated in the appropriate tables. The studies differed significantly with regard to follow-up time, and there were insufficient data in the published reports to allow us to calculate event rates per unit of time; we have used simple proportions (as reported in the studies) instead of rates. Patients were enrolled on the basis of specific criteria that varied among the studies. The criteria for eligible patients excluded those enrolled who were not thought to have tuberculosis at baseline, had resistant organisms, or had a contraindication for the treatment. Specific outcomes evaluated are as follows.
Failure of therapy. Eligible patients who failed to respond to treatment and who had persistent evidence of active disease during the treatment phase were considered to have had treatment failure. Some studies required mycobacteriologic confirmation of failure, whereas others required only clinical evidence of failure or lack of response to therapy.
Cure.
Eligible patients who successfully completed the treatment phase and were alive, without failure, and not lost to follow-up at end of the 6 months of treatment were considered cured.
Loss to follow-up. The proportion of patients who were lost to follow-up, when that information was available, was separated into (A) eligible patients lost to follow-up during the treatment phase, and (B) patients enrolled in the follow-up phase who were lost during that phase.
Deaths. The proportion of patients who died during the study, when data were available, was separated into (A) deaths that occurred among patients eligible for the study during the treatment phase, and (B) deaths that occurred during the posttreatment follow-up phase.
Relapses. Patients enrolled in the follow-up phase were defined as having a relapse of tuberculosis on the basis of either mycobacteriologic or clinical evidence.
Success. The patients cured after 6 months of treatment who were known to be alive, not lost to follow-up, and without relapse at the end of the study were defined as having had treatment success.
Effectiveness. All eligible patients in the study who were known to be alive, not lost to follow-up, and who were not reported as having had treatment failure or relapse by the end of the study were defined as having had effective treatment.
RESULTS
Studies of HIV-Infected Patients
Design. The design of these studies is summarized in table 1. All studies were prospective but varied significantly in design. Four of the studies [12, 14, 16, 17] were randomized and 2 [13, 15] were observational studies of 6-month regimens. Although all study regimens included rifampin, the dosing schedules (daily, twice-weekly, and thrice-weekly) differed among the studies. Some studies used DOT for all patients for all doses. The study by Perriens et al. [12] compared 6-month versus 12-month regimens for treatment of HIV-related tuberculosis and evaluated outcomes among patients both with and without HIV infection, and we restricted our review to the group randomized to 6 months of therapy. The study by Kennedy et al. [14] compared a regimen that contained quinolone with standard therapy. The study by Vernon et al. [16] randomized patients with HIV-related tuberculosis to 1 of 2 continuation-phase regimens (rifampin plus isoniazid or rifapentine plus isoniazid) for a total of 6 months of treatment; we focused on the group assigned therapy with rifampin and isoniazid. The study by ElSadr et al. [17] randomized patients with HIV-related tuberculosis to either 6 or 9 months of therapy; we restricted our review to the group assigned 6 months total therapy. Molecular fingerprinting done by means of restriction fragment length polymorphism (RFLP) analysis was available only in the studies by Vernon et al. [16] and El-Sadr et al. [17] .
The other 2 studies (by Kassim et al. [13] and Chaisson et al. [15] ) were observational nonrandomized studies of 6 months of therapy. The study by Kassim et al. [13] compared the outcome of daily self-administered therapy for HIV-infected with that for uninfected patients. The study by Chaisson et al. [15] used DOT in a thrice-weekly regimen.
In addition to variation in study design and treatment regimens, eligibility criteria varied between these studies (table 1).
Baseline sputum culture positivity was not uniformly required by some of the studies [13, 15] , whereas others required culture positivity [12, 14, 16, 17] . The study by Chaisson et al. [15] was the only one that allowed enrollment of patients with exclusively extrapulmonary tuberculosis. The studies by El-Sadr et al. [16] and Vernon et al. [17] included patients with pansusceptible tuberculosis only. All studies required confirmation of HIV seropositivity either at enrollment or during the study.
Results. Overall, 1000 patients were eligible in these studies, 971 with pulmonary tuberculosis and 29 with intrathoracic tuberculosis. Of eligible patients, 355 (35.5%) had the diagnosis of tuberculosis confirmed by means of culture. The patients eligible in these studies differed in their baseline characteristics (table 2) . When CD4 cell counts were reported, the median ranged from 86 to 475 cells/mm 3 . Patients were primarily middle-aged, and there was substantial variation in sex distribution, with a higher proportion of women in the studies conducted in Zaire and Haiti [12, 15] . Only the study by Kassim et al. [13] indicated the mean duration of symptoms before diagnosis, which was 3-5 months.
Some of the studies required microbiological confirmation of failure, whereas others included patients with either microbiologically confirmed failure or clinical failure (table 1) . Among all series, failure of therapy was rarely reported with the 6-month regimen that contained rifampin (range, 0%-1.9%; table 3). The cure rates reported at the end of the treatment phase ranged from 59.4% to 97.1% (table 3) .
Variable proportions of patients eligible for the study treatment phases were subsequently entered into the follow-up phases; these ranged from 59.4% to 88.6% of eligible patients (table 3) . The duration of follow-up also differed across the studies, from 6 to 22 months from the end of the treatment phase. Overall, the percentages of patients who died were substantial in the studies that provided this information, and they ranged from 20.0% to 41.1%. There were limited data on the causes of deaths in the studies we reviewed. The percentage lost to follow-up was not reported in all of the studies and ranged widely in the 3 that reported these data, from 3.2% to 30.2%.
As in the case of definition of failure of therapy, culture confirmation of a relapse episode of tuberculosis was required in some studies but not in others (table 1). The proportion of patients with relapse ranged from 0 to 10% in these studies (table 3) . Molecular identification by means of RFLP analysis in the studies by Vernon et al. [16] and El-Sadr et al. [17] confirmed that the 3 relapses and 1 relapse, respectively, were truly relapses and not reinfection with new strains of Mycobacterium tuberculosis.
Studies of Patients without HIV Infection
Design. The designs of the selected studies of HIV-uninfected patients are summarized in table 4. The studies by Cohn et al. [19] and Snider et al. [20] were observational and assessed 6 months of therapy that included rifampin that was administered twice a week. The study by Combs et al. [18] was a randomized trial that compared 6 months of therapy with 9 months of therapy, and it used daily therapy; our review focused on the 6-month regimen. The studies by Combs et al. [18] and Snider et al. [20] enrolled patients with pulmonary tuberculosis, and that by Cohn et al. [19] enrolled patients with both pulmonary and extrapulmonary disease. Cohn et al. [19] and Snider et al. [20] used DOT for all patients, whereas in the study by Combs et al. [18] , only patients who demonstrated adherence problems were given DOT. No RFLP analysis was available for these studies. Results. In the 3 studies of patients without HIV infection, 878 patients were considered eligible. Of eligible patients, 874 (99.5%) had confirmed tuberculosis. Results of these studies are shown in table 5. Failure to complete the treatment phase or losses to follow-up during this phase ranged from 9.2% to 28.5%. No episodes of failures of therapy were reported by Cohn et al. [19] and Snider et al. [20] , whereas Combs et al. [18] did not report whether failure of therapy occurred in their study. Differing percentages of patients in these studies successfully completed treatment and were enrolled in the followup phase (table 5). The duration of follow-up from the end of treatment ranged from 18 to 36 months. During the followup phase, the percentage lost to follow-up was not reported in all studies. The percentage of relapse was also low, ranging from 0% to 3.4%.
Summary Outcome Measurements for All Studies
Summary outcomes are shown in table 6. The percentage of patients cured at 6 months varied widely in the studies of HIVrelated tuberculosis, from 59.4% to 97.1%. This is in contrast to studies of patients without HIV infection, which had a narrower range, from 62.3% to 88.0%. The percentage of patients who had a relapse among those who completed the treatment phase and were enrolled in the follow-up phase ranged from 0% to 10% among patients with HIV infection and from 0% to 3.4% among those without HIV infection. Among those with HIV infection, the percentage of patients who were considered to have been successfully treated ranged from 34.0% to 100%, although this percentage is estimated from the data presented in the study by Kennedy et al. [14] , which did not include information on the losses to follow-up or deaths. Success rates were generally higher in the studies of patients without HIV infection. The effectiveness of the regimens varied widely; in the studies of HIV-infected patients with tuberculosis, it ranged from 29.4% to 88.2%; in studies of those without HIV infection, it ranged from 70.6% to 83.8%.
DISCUSSION
The conduct of studies of the treatment of tuberculosis is challenging because of several features of the disease itself and the requirements for its treatment [3] . Because a diagnosis of tuberculosis requires several weeks for confirmation, candidates for tuberculosis treatment studies are often enrolled with only presumptive diagnoses based on clinical features or positive results of smear specimens. The treatment period is long (у6 months), and it may be difficult to ensure that patients continue to take their medications as prescribed. Follow-up after treatment is also extensive (usually 1-3 years or longer) to allow determination of the ultimate effect of the treatment regimen-that is, relapse of disease or not.
A comparison of the results of the various tuberculosis treatment studies we reviewed also presents a challenge. Studies varied significantly in a number of important parameters, including eligibility criteria and case definitions, characteristics of the treatment regimen, method of administering the regimens, definition of failure of therapy, duration of follow-up, and definition of a relapse. The inclusion, in some studies, of subjects with presumptive evidence of tuberculosis may have led to underestimation of failure and relapse and to overestimation of treatment effectiveness, because some patients with presumptive tuberculosis may not have actually had tuberculosis and, therefore, were not at risk of failure or relapse. Similarly, the use of end point definitions for failure or relapse in some studies that included clinically presumed relapses have the potential to overestimate the number of relapses, whereas this may be underestimated in the studies that required confirmation by means of culture. The certainty of the diagnosis of tuberculosis is even more challenging for HIV-infected patients in the absence of culture confirmation. Several reports have indicated that tuberculosis can be mistaken for other opportunistic pulmonary complications [21, 22] . This is particularly important, because radiologic manifestations of HIVrelated tuberculosis may be atypical [21, 23] . Thus, it is possible that episodes of tuberculosis could have been misdiagnosed as other conditions in the absence of requirement of confirmation by means of culture and vice versa. Traditionally, the percentage of patients who completed the treatment phase but developed relapse during the follow-up phase has been the major factor used to determine the success of a tuberculosis treatment regimen, and a value of !5% has been considered acceptable [3] . This standard is based on information derived from treatment studies among HIV-uninfected patients. At first glance, the percentage of patients who experienced relapse appears to be quite low (!5%) in the 3 selected studies of patients without HIV infection. However, the researchers may have underestimated the true number of relapses, because the relapse rate was calculated with regard to only those patients who completed the treatment phase successfully, and the authors made the assumption that no relapses occurred among patients lost to follow-up [3] . Our review revealed a higher percentage of patients with HIV infection who relapsed; however, the higher number of recurrences in these studies may not represent true relapses but, rather, may represent reinfections, because most of the studies did not use confirmation by means of RFLP analysis. Recent studies have reported an unexpectedly high rate of new M. tuberculosis infections after successful completion of treatment [24, 25] . This issue is particularly important for health care professionals who work in settings with high tuberculosis prevalence, in which the risk of exposure to new infections is high [25] , and especially among HIV-infected patients, whose risk of development of tuberculosis after infection is extraordinarily high [8] . Differentiation between the occurrence of a relapse and a new infection has become feasible with the availability of RFLP analysis, which allows the clinician to compare the original isolate with the recurrence isolates [25, 26] . In our review, we found 2 studies conducted among HIVinfected patients that used RFLP analysis [16, 17] . In one study, the recurrences were true relapses [16] , but in the other study, the 1 "relapse" was not confirmed by means of RFLP analysis and it represented a new infection [17] . Both of these studies were conducted in the United States, a country with low tuberculosis prevalence; such confirmation was not available in the studies conducted in Zaire, Ivory Coast, and Haiticountries with high rates of tuberculosis. On the other hand, the relapses reported among HIV-infected patients may have been underestimated, because episodes of tuberculosis may have been mistaken for other opportunistic infections because of the atypical presentation of tuberculosis discussed above and the inability to exclude tuberculosis as a contributor or cause of death in the absence of autopsies.
The limitations with the exclusive use of relapse analysis as an outcome measure that were described above necessitate the consideration of other outcome(s) of tuberculosis treatment. Determination of the effectiveness of a treatment regimen is an important, clinically meaningful outcome, because it indicates the performance of the treatment among all patients treated on an intent-to-treat basis. We used a modified intentto-treat analysis to calculate effectiveness, which took into account the need to exclude patients that were enrolled with a suspected diagnosis but who were later deemed not to have had tuberculosis, and those who were found to have had resistant tuberculosis isolates. The calculation of effectiveness included all eligible patients, irrespective of whether they completed the treatment phase, were lost during follow-up, refused continued participation, or had died. By use of this methodology, we found that, for example, although the percentage of relapses was low among patients without HIV infection, the effectiveness of treatment was more modest, ranging from 70.6% to 83.8%. The lower effectiveness noted in the studies by Combs et al. [18] and Snider et al. [20] reflects the fact that a substantial number of participants did not complete the treatment phase, were lost to follow-up, or died during either the treatment or the follow-up phases. In contrast, the study by Cohn et al. [19] , which had a similarly low percentage of patients who relapsed, had a substantially higher rate of effectiveness; this was due, at least in part, to the fact that a larger percentage of patients completed the treatment phase, the death rate was lower, and fewer patients were lost to follow-up during the posttreatment phase [19] . It is important to note that the calculated effectiveness for many of the studies (table 6) was a maximum estimate, because some studies did not provide the values necessary to accurately calculate effectiveness, such as the number of patients who were lost to follow-up or who died. The use of treatment effectiveness as a preferred outcome for the comparison of studies of HIV-infected patients with those who were not HIV-infected has its own specific limitations, because of high death rates that result from HIV disease [27] . These death rates varied on the basis of the stage of HIV disease among the study participants. Prior AIDS diagnosis, baseline CD4 cell count, and HIV virus load in plasma have been noted to be important predictors of patient outcomes, independent of tuberculosis status [28] [29] [30] [31] . The median CD4 cell count in the studies we reviewed varied widely, and the proportion of patients with a prior AIDS diagnosis at baseline was not uniformly reported across studies. None of the studies included measurements of HIV virus load.
A better assessment of outcomes of treatments for tuberculosis may require taking into account a variety of outcome measures rather than focusing exclusively on the number of relapses. In our review, we identified several potentially useful outcomes (table 6 ). The differences in the study designs and in the characteristics of recruited patients impeded the ability to conduct a valid meta-analysis or a pooled analysis. The inability to calculate actual rates in these studies also significantly limited our attempt to compare the studies. A comparison of percentages for relapses or effectiveness across studies ignores the important element of follow-up time, which varied widely between studies. Presentation of the data in a manner that takes into account duration of follow-up (e.g., events per personyears of follow-up) could facilitate comparison of results between studies. Although, as shown in table 6, higher percentages of relapse and a lower rate of treatment effectiveness were found in studies of HIV-infected patients, it is important not to conclude that 6-month treatment regimens that contain rifampin are inferior for this population because of the aforementioned factors. With the use of more potent antiretroviral therapy and its associated beneficial effect on survival, the outcome of treatment of HIV-related tuberculosis could be dramatically changed [32] . The impact of highly active antiretroviral therapy on the outcome of tuberculosis treatment is an important issue that requires further study.
In conclusion, the available studies of treatment of HIVrelated tuberculosis demonstrate a broad range of effectiveness of 6-month regimens, and the studies do not allow for a precise estimation of those regimens' performance in this population. Future tuberculosis treatment studies need to account for all of the patients who were enrolled in and who were eligible for the study throughout its duration, and to report rates of events rather than percentages. These data, combined with reporting several measures of study outcome, including the percentage of patients who were cured after 6 months of therapy, the therapy's effectiveness, and the rates of relapse, will allow for improved cross-study analysis and for better characterization of the outcomes of specific regimens.
